Inflammation Due to Ulcerative Colitis Treated by IL-7 Receptor Antagonist in Early Study

Inflammation Due to Ulcerative Colitis Treated by IL-7 Receptor Antagonist in Early Study
OSE Immunotherapeutics announced that its interleukin-7 (IL-7) receptor agonist, Effi-7, an immunomodulatory drug being developed for patients with ulcerative colitis, showed positive pre-clinical results. The findings were recently presented at the Federation of Clinical Immunology Societies 2016 Annual Meeting, held in Boston, in a poster titled “IL-7 receptor blockade prevents intestinal human T cells infiltration by modulation of alpha4-beta7

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *